(ENZY) Enzymatica publ - Ratings and Ratios

Enzymatica AB (publ) is a Swedish life science company specializing in the development and commercialization of enzymatic solutions for upper respiratory infections and skin care. Its flagship product, ColdZyme, is a mouth spray designed to reduce the duration and severity of cold and flu symptoms by targeting viral pathogens in the throat. The company also offers enzyme-based formulations for skincare applications. Enzymatica distributes its products through partnerships with global pharmaceutical companies and distributors, who market them under brands such as ViruProtect, STADAProtect, and Bisolviral. Founded in 2007, the company is headquartered in Lund, Sweden, a region known for its robust life science ecosystem. Web URL: https://www.enzymatica.se

From a technical perspective, Enzymaticas stock (Ticker: ENZY) is currently trading at 1.47 SEK, slightly below its 20-day moving average of 1.60. The stocks 50-day moving average is also at 1.60, while the 200-day moving average stands at 1.99, indicating a recent downtrend. The average true range (ATR) of 0.12 reflects relatively low volatility. Over the next three months, the stock is likely to remain range-bound between 1.30 and 1.70, with potential resistance at the 1.60 level and support near the 200-day moving average.

Fundamentally, Enzymatica has a market capitalization of 400.51M SEK, with a price-to-book ratio of 2.31, indicating a premium valuation relative to its book value. The companys forward P/E ratio of 66.67 suggests high expectations for future earnings growth, though its current P/E is 0.00 due to a lack of profitability. The price-to-sales ratio of 8.79 highlights a rich valuation relative to revenue. With a return on equity of -30.15%, the company is currently in a growth phase, reinvesting earnings to expand its product portfolio and distribution network. Over the next quarter, investors should monitor the companys ability to improve profitability and meet its growth targets.